New study suggests novel ehr-based marker can identify at-risk transplant patients and reduce organ rejection
Peer-Reviewed Publication
Updates every hour. Last Updated: 18-Jun-2026 08:16 ET (18-Jun-2026 12:16 GMT/UTC)
Dr. Dan Landau, the Bibliowicz Family Professor of Medicine, and a member of the Sandra and Edward Meyer Cancer Center and the Englander Institute for Precision Medicine at Weill Cornell Medicine, has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.
A new single-protein analysis technique gives researchers an unprecedented ability to study proteins called scramblases, which have critical roles in biology. The development of the new technique, in a study led by investigators at Weill Cornell Medicine and Ruhr University Bochum in Germany, expands the toolkit available to cell biologists and biophysicists and could someday be useful in devising new strategies against multiple diseases.
The International Society for Stem Cell Research (ISSCR) announces today that Bayer is a Founding Member of the ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development, a global cross-sector initiative focused on accelerating the responsible integration of human stem cell-derived models into preclinical drug development.
Co-chaired by Daniela Cornacchia, AstraZeneca, USA, and Shuibing Chen, Weill Cornell Medicine, USA, the consortium is leading a coordinated international effort to advance the regulatory qualification and adoption of human stem cell-derived models, including organoids, engineered tissues, and microphysiological systems, as New Approach Methodologies (NAMs) for drug discovery and development.
A type of white blood cell in the immune system, known as neutrophils, can make cancer immunotherapy less effective. This is shown in a new study from Karolinska Institutet published in the journal Immunity. The results show that a signalling molecule in the tumour affects neutrophils, reducing the effect of treatment.
University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.
In a recent study published in Signal Transduction and Targeted Therapy, scientists found increased survival and tumor-fighting activity in lab and animal models when they blocked a specific protein in the modified cells.